Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2‐overexpressing metastatic breast cancer
Authors:
Open Access
- 15 September 2016
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 107 (10) , 1465-1470
Abstract
Human epidermal growth factor receptor 3 (HER3) expression in lung and breast cancers has a negative impact on survival. Patritumab, a human anti‐HER3 mAb, has shown anticancer activity in preclinical models. This study examined the safety and pharmacokinetics of patritumab in combination with trastuzumab and paclitaxel in patients with HER2‐overexpressing metastatic breast cancer. In this open‐label, multicenter, dose‐escalation, phase Ib study, patients received patritumab 9 or 18 mg/kg plus trastuzumab and paclitaxel at known tolerated doses. Safety and tolerability were assessed based on dose‐limiting toxicities and other non‐life threatening adverse events. The pharmacokinetic profile for patritumab was determined based on the target trough level. Clinical efficacy was evaluated based on the overall response rate and progression‐free survival. Six patients received patritumab 9 mg/kg and 12 received 18 mg/kg. The most common adverse events were diarrhea, alopecia, leukopenia, neutropenia, and maculopapular rash. No dose‐limiting toxicities were observed. The target trough serum concentration was achieved in all patients at a dose of 18 mg/kg. Overall response rate was 38.9% and median progression‐free survival was 274 days. In conclusion, patritumab plus trastuzumab and paclitaxel was tolerable and efficacious at both doses. We recommend the dose level of 18 mg/kg for future phase II studies. (Clinical trial registration: JapicCTI‐121772.)Keywords
Funding Information
- Daiichi-Sankyo
- Eisai
- Pfizer
- Sanofi
- Janssen Pharmaceutica
- Sanofi
- Taiho Pharmaceutical
- AstraZeneca
- Eli Lilly and Company
- Bristol Myers Squibb Foundation
- Boehringer Ingelheim
This publication has 18 references indexed in Scilit:
- Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid TumorsClinical Cancer Research, 2013
- Trastuzumab Emtansine for HER2-Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer TherapyClinical Cancer Research, 2010
- Abstract B171: U3‐1287 (AMG 888), a fully human anti‐HER3 mAb, demonstrates in vitro and in vivo efficacy in NSCLC modelsMolecular Cancer Therapeutics, 2009
- Abstract B167: Identifying first in human (FIH) doses and schedule of U3‐1287 (AMG 888), a fully human anti‐HER3 mAb, based on preclinical pharmacokinetic (PK), pharmacodynamic (PD) and efficacy dataMolecular Cancer Therapeutics, 2009
- Abstract B161: U3-1287 (AMG 888), a fully human anti-HER3 mAb, demonstrates preclinical efficacy in HER2+ and HER2− breast cancer modelsMolecular Cancer Therapeutics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non–Small Cell Lung CancerCancer Research, 2005
- Prognostic value ofERBBfamily mRNA expression in breast carcinomasInternational Journal of Cancer, 2003